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There is limited empiric evidence on the coverage of pneumococcal conjugate vaccines
(PCVs) required to generate substantial indirect protection. We investigate the association
between population PCV coverage and indirect protection against invasive pneumococcal
disease (IPD) and pneumonia hospitalisations among undervaccinated Australian children.
Methods and findings
Birth and vaccination records, IPD notifications, and hospitalisations were individually linked
for children aged <5 years, born between 2001 and 2012 in 2 Australian states (New South
Wales and Western Australia; 1.37 million children). Using Poisson regression models, we
examined the association between PCV coverage, in small geographical units, and the inci-
dence of (1) 7-valent PCV (PCV7)-type IPD; (2) all-cause pneumonia; and (3) pneumococ-
cal and lobar pneumonia hospitalisation in undervaccinated children. Undervaccinated
children received <2 doses of PCV at <12 months of age and no doses at�12 months of
age. Potential confounding variables were selected for adjustment a priori with the assis-
tance of a directed acyclic graph.
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There were strong inverse associations between PCV coverage and the incidence of
PCV7-type IPD (adjusted incidence rate ratio [aIRR] 0.967, 95% confidence interval [CI]
0.958 to 0.975, p-value < 0.001), and pneumonia hospitalisations (all-cause pneumonia:
aIRR 0.991 95% CI 0.990 to 0.994, p-value < 0.001) among undervaccinated children. Sub-
group analyses for children <4 months old, urban, rural, and Indigenous populations showed
similar trends, although effects were smaller for rural and Indigenous populations.
ApproximatelyAU : PerPLOSstyle; numeralsarenotallowedatthebeginningofasentence:PleaseconfirmthattheeditstothesentenceApproximately50%coverageofPCV7amongchildren < 5yearsof :::arecorrect; andamendifnecessary:50% coverage of PCV7 among chi dren <5 y ars of a e was stimat d to
prevent up to 72.5% (95% CI 51.6 to 84.4) of PCV7-type IPD among undervaccinated chil-
dren, while 90% coverage was estimated to prevent 95.2% (95% CI 89.4 to 97.8). The main
limitations of this study include the potential for differential loss to follow-up, geographical
misclassification of children (based on residential address at birth only), and unmeasured
confounders.
Conclusions
In this study, we observed substantial indirect protection at lower levels of PCV coverage
than previously described—challenging assumptions that high levels of PCV coverage (i.e.,
greater than 90%) are required. UnderstandingAU : PleaseconfirmthattheedittothesentenceUnderstandingtheassociationbetweenPCVcoverageandindirectprotectionis:::didnotaltertheintendedthoughtofthesentence:the association between PCV cov rage and
indirect protection is a priority since the control of vaccine-type pneumococcal disease is a
prerequisite for reducing the number of PCV doses (from 3 to 2). Reduced dose schedules
have the potential to substantially reduce program costs while maintaining vaccine impact.
Author summary
Why was this study done?
• Pneumococcal conjugate vaccines (PCVs) reduce the burden of pneumococcal disease
in vaccinated and unvaccinated populations through both direct and indirect (herd)
effects.
• The indirect effects of a vaccine comprise a substantial component of overall vaccine
impact, contributing to the cost-effectiveness of the vaccine, but little is known about
what factors contribute to herd protection, including vaccination coverage.
• In this study, we examined associations between PCV coverage and indirect effects
within diverse populations in Australia.
What did the researchers do and find?
• Using a large dataset of 1.3 million children from 2 states in Australia, we quantified the
relationship between PCV coverage within small geographical units and indirect protec-
tion against pneumococcal disease. We also performed similar analyses for infants too
young to be fully vaccinated, urban, rural, and Indigenous populations.
• There were strong inverse relationships between PCV coverage and the incidence of
severe invasive disease due to vaccine types and pneumonia hospitalisations among
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undervaccinated children, i.e., higher coverage was associated with greater reductions in
disease due to indirect effects. We also found substantial indirect effects at relatively low
levels of PCV coverage. We estimated that 50% and 90% coverage of 7-valent PCV
(PCV7) among children under 5 years of age prevented almost three-quarters (72.5%,
95% confidence interval [CI] 51.6 to 84.4) and almost all (95.2%, 95% CI 89.4 to 97.8) of
PCV7-type severe invasive disease, respectively. For pneumonia, we estimated that 50%
and 90% coverage was sufficient to prevent one-third (33.3%, 95% CI 27.3 to 38.8) and
about half (51.7%, 95% CI 43.7 to 58.6) of all-cause pneumonia hospitalisations among
undervaccinated children.
• These trends were similar for children less than 4 months old, urban, rural, and Indige-
nous populations, although these effects were smaller for rural and Indigenous popula-
tions. There was also a trend towards decreasing incidence of PCV13-type IPD among
undervaccinated children as PCV13 coverage increased.
What do these findings mean?
• Our results challenge existing assumptions that high PCV coverage is required to
achieve substantial indirect protection.
• Understanding the determinants of indirect effects are particularly urgent as countries
that have controlled vaccine-type pneumococcal disease consider using reducing the
number of PCV doses (from 3 to 2). Reduced dose schedules have the potential to signif-
icantly lower program costs while maintaining vaccine impact, providing indirect pro-
tection is achieved and preserved.
Introduction
Infections due to Streptococcus pneumoniae, the pneumococcus, are a leading cause of morbid-
ity and mortality among children globally [1]. Pneumococcal conjugate vaccines (PCVs) have
been successful in reducing pneumococcal disease through the direct protection of vaccinated
individuals and indirect protection of both vaccinated and unvaccinated individuals [2]. Fol-
lowing the introduction of PCV to childhood immunisation schedules, many high-income
countries, including Australia, have observed the near elimination of vaccine-type (VT) inva-
sive pneumococcal disease (IPD) with impacts extending beyond targeted age groups due to
reduced transmission of VT pneumococci [3–5].
The 13-valent PCV (Prevnar 13, Pfizer) and 10-valent PCV (Synflorix, GSK) are costly, and
infant immunisation schedules are becoming increasingly crowded due to multiple vaccines.
Therefore, a PCV schedule comprising only 2 doses as opposed to 3 or 4 doses, once VTs have
been controlled, is an attractive policy option [6]. In 2020, the United Kingdom became the
first country to move to a 2-dose (1 + 1) schedule for 13-valent PCV (PCV13) in the childhood
vaccination program [7]. However, evidence to support the use of 1 + 1 schedules in settings
with low or heterogeneous vaccine coverage is not available.
Conceptually, the population-level indirect effects of vaccination programs are achieved
through sufficient vaccination coverage among age groups primarily responsible for
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transmission [8,9]. With sufficient indirect effects, near elimination of VT transmission and
disease can be achieved. Near elimination of VT disease has largely occurred in settings that
have rapidly reached very high rates of coverage; hence, it is often assumed that high PCV cov-
erage is required to achieve elimination, but there is limited evidence for this [10]. Settings
with lower rates of coverage often lack the disease surveillance required to demonstrate the
indirect effects of vaccines. It is therefore not clear whether VT elimination is possible for
nearly half of the countries that have introduced PCV, which have less than 90% PCV coverage
[11]. To date, most studies evaluating indirect effects from PCV have used aggregate data and
ecological study designs, such as before-and-after or time-series analyses. Few have incorpo-
rated PCV coverage into their analyses.
Australia is a geographically diverse setting with a combination of dense urban populations
and sparsely populated rural areas. Within Australia, Aboriginal and Torres Strait Islander
children (henceforth referred to as Indigenous children) experience significantly higher rates
of morbidity across a range of infectious diseases including pneumococcal disease, likely
related to higher levels of social disadvantage [12,13]. Pre-PCV introduction, IPD rates in
Indigenous children from Central Australia were some of the highest in the world [14].
In June 2001, 7-valent PCV (PCV7) was introduced for high-risk children, including Indig-
enous children and children with specified medical conditions, at ages 2, 4, and 6 months.
Children who were medically at risk received a fourth dose of PCV7 at 12 months and a dose
of 23-valent pneumococcal polysaccharide vaccine (PPV23) at 5 years of age, while Indigenous
children in high-incidence jurisdictions received PPV23 at 18 to 24 months of age. A 3-dose
PCV program (2, 4, and 6 months) became universal in January 2005, with catch-up doses for
children aged less than 2 years of age. In July 2011, PCV13 replaced PCV7 with a catch-up pro-
gram funding a supplemental dose of PCV13 for children 12 to 35 months of age [15]. For
Indigenous children in high-incidence jurisdictions, a fourth dose of PCV13 replaced the
PPV23 vaccine at 18 to 23 months.
Using the same large linked immunisation and hospitalisation dataset, indirect protection
following PCV introduction previously in Australia has been reported previously at the state
level for children less than 2 years of age, register with all-cause pneumonia declining among
unvaccinated Indigenous (12% reduction; 95% confidence interval [CI] 3 to 25) and non-
Indigenous children (45% reduction; 95% CI 41 to 49) [16].
In this study, we extended this analysis by examining the association between PCV coverage
in small geographic units within 2 states for both incidence of IPD and hospitalised pneumo-
nia among undervaccinated children, in periods when coverage was changing rapidly. Our
study provides a unique opportunity to evaluate indirect protection against pneumococcal dis-
ease in the absence of the widespread use of the booster dose, making this analysis more appli-




Our study design was a retrospective population-based cohort that used a subset of children
under 5 years of age from a dataset of all children born in New South Wales (NSW) and West-
ern Australia (WA) between 2001 and 2012, a combined birth cohort of approximately 1.37
million [18]. Birth records were probabilistically linked (using name, date of birth, residential
address, and sex) to health data including vaccination register, IPD notification data, and hos-
pitalisation data [18].
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Linked data sources
Vaccination status was obtained from the Australian Childhood Immunisation Register
(ACIR), which includes all children enrolled in the publicly funded healthcare system and
comprises approximately 99% of children in Australia by age 12 months [19]. IPD cases,
defined as isolation of S. pneumoniae by culture or detection of nucleic acid from a normally
sterile site, are notified as part of state-based passive surveillance systems [19]. Hospitalisation
data covered all inpatient separations (discharges, transfers, and deaths) and included primary
diagnosis and up to 50 (NSW) or 20 (WA) secondary diagnoses (coded using the Australian
version of the International Classification of Diseases [ICD-AM] coding system). IPD data
were available from January 2001 onwards, while hospitalisation data were available from July
2001 onwards. Demographic and health risk factor data were obtained from state perinatal
data collection and birth registries (Table A in S1 File) [19]. See Fig A in S1 File for a flow
chart of the study cohort and data sources.
Study definitions
PCV7-type IPD was defined as IPD due to serotypes in PCV7, i.e., serotypes 4, 6B, 9V, 14,
18C, 19F, and 23F. PCV13, non-PCV7-type IPD was defined as IPD due to the additional 6
serotypes in PCV13, i.e., serotypes 1, 3, 5, 6A, 7F, and 19A. For all-cause pneumonia, we iden-
tified all hospitalisations with a pneumonia-related diagnostic code in the principal or addi-
tional diagnosis fields. Pneumococcal or lobar pneumonia hospitalisations were restricted to
hospitalisations coded as either pneumococcal pneumonia (J13) or lobar pneumonia (J18.1)
(Table B in S1 File). Interhospital transfers and admissions within 14 days of a previous separa-
tion date were merged and classified as a single episode as per previous analyses [20]. All out-
comes were evaluated for children under 5 years of age.
We defined a child as vaccinated with PCV if they received an adequate number of doses to
develop a protective immune response against vaccine serotypes at least 14 days prior to onset
of any study outcomes, i.e., 2 or more PCV doses administered at less than 12 months of age,
or at least 1 PCV dose administered after the age of 12 months [21]. Otherwise, cases were clas-
sified as undervaccinated. Given children who have received 1 dose of PCV at less than 12
months of age may have partial protection, we have also completed sensitivity analyses exam-
ining indirect effects among completely unvaccinated children.
Statistical analyses
For descriptive analyses of PCV coverage over time, we calculated and graphed coverage
among children less than 5 years of age at 3-monthly intervals (31 March, 30 June, 30 Septem-
ber, and 31 December) from 2001 to 2012. For example, PCV coverage among children less
than 5 years of age at the final quarter of 2012 (assessed at 31 December) would be calculated
for those born between 31 December 2007 and 30 December 2012. Coverage was calculated
among children under 5 years of age to aid comparison with previous studies [22,23] and
because previous research suggests that vaccination of children up to 5 years of age are key for
the generation of indirect effects [22,24].
To visualise any geographic heterogeneity in PCV coverage, PCV coverage was mapped
within statistical local areas (SLAs) among children under 5 years of age at 3 time points—
December 2005, December 2009, and December 2012. The 3 time points were chosen to repre-
sent the early post-PCV7 period, the late post-PCV7 period, and the early PCV13 period. SLAs
are the second smallest geographical spatial unit used by the Australian Bureau of Statistics
[25]. In NSW and WA, there are 199 and 155 SLAs, respectively. SLAs vary in population size
from less than 100 children in some rural areas to around 11,000 children under 5 years of age
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in urban areas. SLAs with fewer than 100 children under 5 years of age were excluded to enable
meaningful estimates of PCV coverage for the different age groups.
Crude rates of IPD and pneumonia hospitalisation among all children and undervaccinated
children under 5 years of age over 3 time periods were calculated: targeted PCV program
(2001 to 2004), universal PCV7 program (2005 to 2010), and universal PCV13 program (2011
to 2012). Person-time for each child started at birth and was censored at the earliest of the fol-
lowing: death, when the child reached 5 years of age or at the end of the study period. For the
undervaccinated group, person-time was also censored when the child was considered vacci-
nated as previously defined.
To determine the association between PCV coverage and indirect effects against IPD and
hospitalised pneumonia (primary analysis), we first calculated the incidence of each disease
outcome during the person-time for which children were undervaccinated up to 5 years of
age. We divided each child’s undervaccinated person-time into successive 3-month intervals
and linked the intervals to PCV coverage in their SLA of residence at that same time period.
SLA of residence was based on mother’s residence at child’s birth. Using Poisson regression
models, we examined the association between SLA-level PCV coverage and disease incidence
in undervaccinated children. We used robust variance estimates to account for clustering,
accommodating multiple coverage estimates for each individual and checked linearity assump-
tions by plotting the log of the disease rates against PCV coverage.
Analyses relating to PCV7-type IPD used the full study period from January 2001 and
December 2012, while analyses relating to PCV13, non-PCV7-type IPD were restricted to
from January 2009 onwards to 18 months prior to PCV13 introduction. Analyses relating to
pneumonia hospitalisations used data from July 2001 onwards due to lack of availability of
hospitalisation data in NSW prior to this date.
Potential confounding variables were selected a priori using a directed acyclic graph
(DAG), informed by relevant literature, and refined through expert consultation (S1 File, pp
6). These were age group, calendar year, Indigenous status, season, Index of Relative Socio-
economic Advantage and Disadvantage (IRSAD) score, Accessibility or Remoteness Index of
Australia (ARIA) category, birth weight, gestational age, maternal smoking during pregnancy,
number of previous pregnancies, and previous hospitalisation with an ICD code correspond-
ing to the presence of a medical condition increasing risk of IPD.
We graphed predicted incidence rates of each outcome among undervaccinated children
under 5 at each decile of PCV coverage, accounting for the balance of covariates across all the
individuals [26]. We also calculated the estimated population preventable fraction of
PCV7-type IPD and all-cause pneumonia hospitalisations for each decile of PCV coverage,
defined as the proportion of disease among undervaccinated children estimated to be prevent-
able by increasing vaccine coverage among different age groups [27].
We conducted subgroup analyses, examining PCV7-type IPD and all-cause pneumonia
hospitalisations among (1) children too young to be vaccinated (under 4 months of age); (2)
undervaccinated children in urban and rural Australia; and (3) undervaccinated Indigenous
children. We expected that associations for these subgroups may vary as the relationship
between PCV coverage and pneumococcal disease is modulated by the dynamics of pneumo-
coccal transmission, which, in turn, differs with population density, age group, risk factors,
and household structure [13,28].
This study is reported as per the REporting of studies Conducted using Observational Rou-
tinely-collected Data (RECORD) guideline (S1 RECORD Checklist). Statistical analyses were
performed according to a prospective data analysis plan (see S1 Text).
Ethical approval was obtained from the following: The Aboriginal Health and Medical
Research Council Ethics Committee (approval ID: 931/13), AIHW Ethics Committee
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(approval ID: EC 2012/4/62), Department of Health Human Research Ethics Committee
(approval ID: 1/2013), Department of Health–WA Human Research Ethics Committee
(approval ID: 2012/75), NSW Population and Health Service Research Ethics Committee
(approval ID: HREC/13/CIPHS/15), and Western Australian Aboriginal Health Ethics Com-
mittee (approval ID: 459).
Results
Study cohort and outcomes
The cohort comprised 1,365,893 singleton children born between January 2001 and December
2012, of which 1,223,803 lived in urban areas, 106,470 lived in rural areas, and 66,484 were
Indigenous [16,29]. The characteristics of this cohort are described in Table 1. During
5,852,233 person-years of follow-up among children under 5 years of age, 1,427 cases of IPD
were notified: 43.2% due to PCV7 serotypes, 28.4% due to PCV13–non-PCV7 serotypes,
17.7% due to non-PCV serotypes, and 10.7% lacked serotype data. Over the same period,
34,757 children experienced at least 1 episode of pneumonia hospitalisation, of which 799
(2.3%) were coded as pneumococcal or lobar pneumonia. Children were undervaccinated
against any PCV during 1,823,401 person-years of follow-up (31.2% of total person-years),
with 83% of this time in children who had received no PCV doses.
Incidence of invasive pneumococcal disease (IPD) and pneumonia
hospitalisations by period
Among undervaccinated children, rates of all-cause IPD decreased from 73.3 in the targeted
PCV7 period to 17.1 per 100,000 person-years in the universal PCV13 period (Table 2). Rates
of PCV13, non-PCV7-type IPD increased in the universal PCV7 period, before decreasing in
the universal PCV13 period (Table 2). In the universal PCV7 period, rates of PCV7-type IPD
were higher in undervaccinated children compared to all children. Comparable trends were
observed among different age groups and among both Indigenous and non-Indigenous chil-
dren (Table D in S1 File). Annual rates of PCV7 and PCV13, non PCV7-type IPD, are pre-
sented alongside annual PCV coverage estimates in Tables E and F in S1 File.
Among undervaccinated children, rates of all-cause pneumonia decreased from 90.7 to 50.3
per 10,000 person-years from targeted PCV7 to universal PCV13 periods (Table 3). Substantial
reductions were observed for both all-cause pneumonia and pneumococcal or lobar pneumo-
nia across different age groups by vaccination period (Table G in S1 File).
PCV coverage
Among children under 5 years, coverage of any PCV increased steeply to 40% reflecting a
catch-up program up to 2 years of age, then more gradually over the next 4 years as vaccinated
children aged into older age groups, reaching 86% by December 2012 (Fig 1).
Figs 2 and 3 depict the geographical heterogeneity in PCV coverage at the SLA level among
children aged 12 to 23 months at the end of each of the following years: 2005, 2009, and 2012,
with greatest heterogeneity in the year of universal PCV introduction (2005). The median and
interquartile ranges of SLA-level PCV coverage by year are presented in Tables E and F in
S1 File.
PCV coverage and indirect protection against vaccine-type IPD
Fig 4 shows the association between PCV coverage and incidence of PCV7-type IPD for
undervaccinated children aged under 5 years. The number of IPD cases and the
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undervaccinated person-time available for analysis at different levels of PCV coverage are pro-
vided in Table H in S1 File.
For each percentage point increase in PCV coverage among children 0 to 59 months of age,
the adjusted incidence of PCV7-type IPD decreased by 3.3% (95% CI 2�5 to 4�2,<0.001)
among undervaccinated children under 5 years of age (Table 4). The steepest declines in
PCV7-type IPD occurred between 0% and 50% coverage among children 0 to 59 months of
age (Fig 4).
Additionally, incidence of PCV13-type IPD among undervaccinated children decreased as
PCV13 coverage increased; however, CIs crossed the null value (adjusted incidence rate ratio
[aIRR] 0.989; 95% CI 0.971 to 1.007; p = 0.241) (Fig 4 and Table 4).
Subgroup analyses among children less than 4 months of age, children living in urban
areas, children living in rural areas, and Indigenous children showed similar trends, although
CIs for Indigenous and rural subgroup analyses were wide as sample sizes were small (see Fig 5
Table 1. Cohort characteristics by Indigenous status, New South Wales and Western Australia, 2001–2012.
Non-Indigenous, n (%), N = 1,299,409 Indigenous, n (%), N = 66,484
State of birth registration New South Wales 993,936 (76.5) 45,551 (68.5)
Western Australia 305,473 (25.5) 20,933 (31.5)
Sex Male 668,021 (51.4) 34,284 (51.6)
Female 631,388 (48.6) 32,200 (48.4)
Socioeconomic index 91%–100% (least disadvantaged) 160,519 (12.4) 990 (1.5)
76%–90% 199,055 (15.3) 2,739 (4.1)
26%–75% 582,833 (44.9) 21,704 (32.7)
11%–75% 196,074 (15.1) 15,371 (23.1)
0%–10% (most disadvantaged) 126,124 (9.7) 21,996 (33.1)
Missing 34,804 (2.7) 3,684 (5.5)
Remoteness index Major cities (urban) 989,470 (76.2) 27,633 (42.6)
Inner regional (urban) 189,454 (14.6) 17,246 (25.9)
Outer regional (rural) 71,056 (5.5) 10,899 (16.4)
Remote (rural) 13,681 (1.1) 4,813 (7.2)
Very remote (rural) 3,310 (0.3) 2,711 (4.8)
Missing 32,438 (2.5) 3,182 (4.8)
Number of previous pregnancies (parity) 0 520,276 (40.0) 22,119 (33.3)
1 434,073 (33.4) 16,512 (24.8)
2 205,396 (15.8) 11,002 (16.6)
�3 138,257 (10.6) 16,786 (25.3)
Birthweight (g) <1,500 7,105 (0.6) 833 (1.3)
1,500–2,499 45,846 (3.5) 5,417 (8.2)
2,500–3,499 668,358 (51.4) 36,029 (54.2)
3,500–4,499 555,005 (42.7) 23,126 (34.8)
�4,500 22,771 (1.8) 1,065 (1.6)
Missing 324 (0.0) 14 (0.0)
Prematurity (gestational age <33 weeks) Preterm 8,539 (0.7) 993 (1.5)
Missing 156 (0.0) 30 (0.1)
Parental smoking Yes 151,309 (11.6) 30,309 (45.6)
No 1,145,210 (88.1) 36,094 (54.2)
Missing 2,890 (0.2) 81 (0.1)
Hospital admission aged <6 weeks 193,020 (14.9) 13,566 (20.4)
Any hospital admission for risk condition 47,705 (3.7) 3,382 (5.1)
https://doi.org/10.1371/journal.pmed.1003733.t001
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and Table I in S1 File). Sensitivity analyses among completely unvaccinated children yielded
similar results (Tables J and K in S1 File).
Table 5 shows the estimated preventable fraction of PCV7-type IPD in undervaccinated
children less than 5 years of age for each decile increase in PCV coverage. Vaccinating half of
children less than 5 years of age is estimated to prevent 81.4% (95% CI 71.2 to 88.0) of
PCV7-type IPD, while 90% coverage prevents 95.2% (95% CI 89.4 to 97.8).
PCV coverage and indirect protection against pneumonia hospitalisations
Similarly, there were inverse associations between PCV coverage and incidence of both all-
cause pneumonia and pneumococcal or lobar pneumonia hospitalisations among undervacci-
nated children (Fig 6 and Table 6). The number of pneumonia hospitalisations and
Table 2. Rates of IPD among all children and undervaccinated children� by vaccination period, New South Wales and Western Australia, 2001–2012.
All children Undervaccinated children (PCV13)
Cases/person-years IPD rate (95% CI)† Cases/person-years IPD rate†
All-cause IPD
Targeted PCV7 (2001–2004) 603/835,128 7.2 (6.7–7.8) 595/811,740 7.3 (6.7–7.9)
Universal PCV7 (2005–2010) 595/3,275,465 1.8 (1.7–2.0) 181/944,751 1.9 (1.7–2.2)
Universal PCV13 (2011–2012) 225/1,741,640 1.3 (1.2–1.5) 30/175,044 1.7 (1.2–2.5)
PCV7-type IPD
Targeted PCV7 (2001–2004) 460/835,333 5.5 (5.0–6.0) 455/811,919 5.6 (5.1–6.1)
Universal PCV7 (2005–2010) 144/3,276,676 0.4 (0.4–0.5) 103/945,020 1.1 (0.9–1.3)
Universal PCV13 (2011–2012) 13/1,742,423 0.1 (0.0–0.1) 3/175,090 0.2 (0.1–0.5)
PCV13, non-PCV7-type IPD
Targeted PCV7 (2001–2004) 29/833,868 0.4 (0.2–0.5) 29/835,868 0.4 (0.2–0.5)
Universal PCV7 (2005–2010) 265/3,277,575 0.8 (0.7–0.9) 265/3,277,444 0.8 (0.7–0.9)
Universal PCV13 (2011–2012) 111/1,741,984 0.6 (0.5–0.8) 101/1,282,026 0.8 (0.7–1.0)
�Undervaccinated for both PCV7 and PCV13.
†Per 10,000 person-years.
IPDAU : AbbreviationlistshavebeencompiledforthoseusedinTables2   7:Pleaseverifythatallentriesarecorrect:, invasive pneumococcal disease; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
https://doi.org/10.1371/journal.pmed.1003733.t002
Table 3. Rates of pneumonia hospitalisations among all children and undervaccinated children�, New South Wales and Western Australia by vaccination period,
2001–2012.
All children Undervaccinated children (PCV13)
Cases/person-years Hospitalisation rate† (CI) Cases/person-years Hospitalisation rate† (CI)
All-cause pneumonia hospitalisations
Targeted PCV7 (2001–2004) 7,704/811,760 94.9 (92.8–97.0) 7,156/788,957 90.7 (88.6–92.8)
Universal PCV7 (2005–2010) 18,026/3,229,066 55.8 (55.0–56.6) 4,589/931,337 49.3 (47.9–50.7)
Universal PCV13 (2011–2012) 9,009/1,720,705 52.4 (51.3–53.4) 876/174,256 50.3 (47.0–53.7)
Pneumococcal or lobar pneumonia hospitalisations
Targeted PCV7 (2001–2004) 284/820,697 3.5 (3.1–3.9) 266/812,094 3.3 (2.9–3.7)
Universal PCV7 (2005–2010) 364/3,275,939 1.1 (1.0–1.2) 100/945,250 1.1 (0.9–1.3)
Universal PCV13 (2011–2012) 158/1,744,642 0.9 (0.8–1.1) 18/175,070 1.0 (0.6–1.6)
�Undervaccinated for both PCV7 and PCV13.
†Per 10,000 person-years.
PCV7, 7-valent PCV; PCV13, 13-valent PCV.
https://doi.org/10.1371/journal.pmed.1003733.t003
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undervaccinated person-time at the different levels of PCV coverage are provided in Table L
in S1 File. For each percentage point increase in PCV coverage among children less than 5
years of age, the adjusted incidence of pneumococcal or lobar pneumonia hospitalisations
decreased by approximately 1.5% (95% CI 0.7 to 2.6; p = 0.001) (Table 6). For each percentage
Fig 1. Quarterly coverage� of any PCV and PCV13 among children under 5 years of age, New South Wales and
Western Australia, 2001–2012. �Vaccinated defined as 2 or more PCV doses administered at<12 months of age or at
least 1 PCV dose administered after the age of 12 months. PCVAU : AbbreviationlistshavebeencompiledforthoseusedinFigs1   6:Pleaseverifythatallentriesarecorrect:, pneumococcal conjugate vaccine; PCV13, 13-valent
PCV; WA, Western Australia.
https://doi.org/10.1371/journal.pmed.1003733.g001
Fig 2. Coverage� of any PCV among children less than 5 years of age by SLA and year, New South Wales, 2001–
2012; top row: New South Wales (state), bottom row: Sydney (capital city); SLAs coloured white have been
excluded due to small numbers of children. �Vaccinated defined as 2 or more PCV doses administered at<12
months of age or at least 1 PCV dose administered after the age of 12 months. SLA digital boundaries (ASGC 2006) for
this map were obtained from the Australian Bureau of Statistics (https://www.abs.gov.au/) CC BY 4.0. PCV,
pneumococcal conjugate vaccine; SLA, statistical local area.
https://doi.org/10.1371/journal.pmed.1003733.g002
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point increase in PCV coverage among children 0 to 59 months of age, the adjusted incidence
of all-cause pneumonia hospitalisations decreased by approximately 0.9% (95% CI 0.6 to 1.0;
p< 0.001) (Table 6).
Fig 3. Coverage� of any PCV among children 12–23 months of age by SLA and year, Western Australia, 2001–
2012; top row: Western Australia (state), bottom row: Perth (capital city); SLAs coloured white have been
excluded due to small numbers of children. �Vaccinated defined as 2 or more PCV doses administered at<12
months of age or at least 1 PCV dose administered after the age of 12 months. SLA digital boundaries (ASGC 2006) for
this map were obtained from the Australian Bureau of Statistics (https://www.abs.gov.au/) CC BY 4.0. PCV,
pneumococcal conjugate vaccine; SLA, statistical local area.
https://doi.org/10.1371/journal.pmed.1003733.g003
Fig 4. Estimated rate of VT IPD incidence� and 95% CIs (blue shading) among undervaccinated children under 5 years, at each decile of PCV coverage, New
South Wales and Western Australia, 2001–2012. �PCV13, non-PCV7-type IPD incidence was only estimated up to 60% as there were few data points available. CI,
confidence interval; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV; VT, vaccine-type.
https://doi.org/10.1371/journal.pmed.1003733.g004
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Subgroup analyses for all-cause pneumonia hospitalisations among children living in urban
areas, children living in rural areas, and Indigenous children showed similar trends, although,
again, CIs for Indigenous and rural subgroup analyses were wide as there were fewer cases and
individuals in these subgroups (Table M in S1 File).
Table 7 shows the preventable fraction of all-cause pneumonia hospitalisations in undervac-
cinated children less than 5 years of age by each decile increase in PCV coverage. We estimate
that vaccinating 50% of children less than 5 years of age will prevent 33.3% (95% CI 27.3 to
38.8) of all-cause pneumonia hospitalisations in undervaccinated children less than 5 years,
while vaccinating 90% prevents 51.7% (95% CI 43.7 to 58.6).
Table 4. Crude and adjusted� incidence rate ratios of PCV7-type IPD among undervaccinated children under 5 years, by percent increase in PCV coverage† among
children under 5 years of age, New South Wales and Western Australia, 2009–2012.
Crude Adjusted�
Incidence rate ratio (95% CI) p-value Incidence rate ratio
(95% CI)
p-value
PCV7-type IPD (n = 8,579,771§) 0.965 (0.961–0.969) <0.001 0.967 (0.958–0.975) <0.001
PCV13, non-PCV7-type IPD (n = 8,941,562§) 0.985 (0.972–0.998) 0.029 0.989 (0.971–1.007) 0.241
�Adjusted by Indigenous status, season, IRSAD score, ARIA category, birth weight, gestational age, maternal smoking during pregnancy, number of previous
pregnancies, and previous hospitalisation for a range of high-risk medical comorbidities.
†Coverage of any PCV—inclusive of both PCV7 and PCV13.
§Number of observations for adjusted analysis (quarterly person-time).
ARIA, Accessibility or Remoteness Index of Australia; CI, confidence interval; IPD, invasive pneumococcal disease; IRSAD, Index of Relative Socio-economic
Advantage and Disadvantage; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
https://doi.org/10.1371/journal.pmed.1003733.t004
Fig 5. Estimated rate of VT IPD incidence� and 95% CIs (blue shading) among 3 subgroups of undervaccinated
children under 5 years (urban, rural, and Indigenous), at each decile of PCV coverage, New South Wales and
Western Australia, 2001–2012. CI, confidence interval; IPD, invasive pneumococcal disease; PCV, pneumococcal
conjugate vaccine; PCV7, 7-valent PCV; VT, vaccine-type.
https://doi.org/10.1371/journal.pmed.1003733.g005
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Discussion
The findings from our novel analyses indicate that relatively low levels of coverage are required
to generate indirect protection in children against IPD and pneumonia hospitalisations in
Australia. These results challenge previous understandings that high coverage is required for
substantial indirect protection. Consistent with previous studies, our estimates indicate an
inverse relationship between PCV coverage and indirect effects on VT IPD [30]. A meta-analy-
sis of PCV impact studies reported a 0.5% reduction in IPD (95% credible interval 0.2% to
1.1%) among children and adults for each percentage increase in vaccine coverage among chil-
dren, accounting for country-level confounders [31]. However, in contrast to previous pneu-
mococcal carriage studies, which reported statistically significant indirect effects at 58% to
75% coverage, we estimated substantial indirect effects at lower rates of PCV coverage
[22,23,32]. While not directly comparable, the indirect effects of PCV against disease can be
expected to reflect indirect effects on carriage, since these effects are mediated by reductions in
carriage [24]. The variation in results may be due to differences in analytic method. Compared
Table 5. Preventable fraction of PCV7-type IPD in undervaccinated children under 5 years at deciles of PCV cov-
erage, New South Wales and Western Australia, 2001–2012.










IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV.
https://doi.org/10.1371/journal.pmed.1003733.t005
Fig 6. Estimated rate of pneumonia hospitalisation and 95% CIs (blue shading) among undervaccinated children at each decile of PCV
coverage, New South Wales and South Australia, 2001–2012. CI, confidence interval; PCV, pneumococcal conjugate vaccine.
https://doi.org/10.1371/journal.pmed.1003733.g006
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to annual carriage surveys conducted by Hammitt and colleagues [32], we analysed at quar-
terly intervals allowing us to detect indirect effects at lower coverage rates. Grant and col-
leagues defined indirect effects as a statistically significant reduction in VT carriage
prevalence, a measure that depends on both the effect size and sample size [23]. While Lough-
lin and colleagues chose to define indirect effects a priori as a 50% decline in VT carriage [22].
By modelling the association, we were able to quantify the estimated degree of indirect effects
at varying coverage rates, facilitating future comparisons between studies with varying sample
sizes and methods. Differences in the relationship between PCV coverage and indirect effects
between studies may also be due to differences in the vaccine type studied (i.e., PCV7, PCV10,
or PCV13) or context.
Importantly, we found similar trends among rural populations and Indigenous popula-
tions, although these effects were smaller and had large confidence intervals, which likely
reflects the smaller sample size available for analysis. These findings are important as they
reflect the estimated indirect effects in different settings with different patterns of social mixing
and therefore patterns of pneumococcal disease transmission. The modelled incidence of
PCV7-type disease at zero coverage was lower than expected, given Indigenous children are
known to be at high risk of pneumococcal disease. This is likely due to the earlier introduction
of PCV for Indigenous children in 2001, which meant undervaccinated Indigenous children
were already benefiting from some degree of indirect effects at the start of our study’s
Table 6. Crude and adjusted� incidence rate ratios of pneumonia hospitalisations among undervaccinated children under 5 years, by percent increase in PCV cover-
age† among children under 5 years of age, New South Wales and Western Australia, 2009–2012.
Crude Adjusted
Incidence rate ratio (95% CI) p-value Incidence rate ratio (95% CI) p-value
Pneumococcal or lobar pneumonia hospitalisation (n = 6,885,749§) 0.980 (0.976–0.984) <0.001 0.985 (0.974–0.993) 0.001
All-cause pneumonia hospitalisation (n = 6,794,370§) 0.993 (0.992–0.994) <0.001 0.991 (0.990–0.994) <0.001
�Adjusted by Indigenous status, age group, season, IRSAD score, ARIA category, birth weight, gestational age, maternal smoking during pregnancy, number of previous
pregnancies, and previous hospitalisation for a range of high-risk medical comorbidities.
†Any PCV—inclusive of both PCV7 and PCV13.
§Number of observations for adjusted analysis (quarterly person-time).
ARIA, Accessibility or Remoteness Index of Australia; CI, confidence interval; IRSAD, Index of Relative Socio-economic Advantage and Disadvantage; PCV,
pneumococcal conjugate vaccine.
https://doi.org/10.1371/journal.pmed.1003733.t006
Table 7. Preventable fraction of all-cause pneumonia hospitalisations in undervaccinated children under 5 years
at deciles of PCV coverage, New South Wales and Western Australia, 2001–2012.










PCV, pneumococcal conjugate vaccine.
https://doi.org/10.1371/journal.pmed.1003733.t007
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observation period. Without sufficient baseline data prior to vaccine introduction, our analy-
ses likely underestimate the full extent of indirect effects among Indigenous children. Given
that Indigenous children make up 17.3% of our rural cohort, the earlier introduction of PCV
among Indigenous children may also have impacted on our estimates of indirect effects in
rural settings. However, the low baseline rates of disease may also be attributable to a more
sparsely populated rural population with less social mixing compared to urban settings [33].
Previous studies on the direct effect of PCV found the vaccine to be equally effective among
Indigenous children and children from rural areas, suggesting that our results are not due to
reduced vaccine effectiveness in these groups. Evidence of indirect effects among children
under 4 months of age, albeit not statistically significant, is also important to note since these
children are too young to be fully vaccinated across the time period while vaccine eligibility
and coverage change for other age groups.
Our analyses also indicated that increasing indirect protection against pneumonia hospita-
lisations was associated with rising PCV coverage. Pneumonia comprises a substantially larger
disease burden than IPD and is a crucial determinant of vaccine cost-effectiveness of a PCV
program. Our findings are consistent with previous analysis using the same dataset, which
found 38% and 28% reductions in all-cause pneumonia hospitalisations among children <2
and 2 to 4 years of age, respectively, 2 years post-PCV7 introduction in Australia [34]. Similar
relationships have been reported for PCV uptake and pneumonia hospitalisations in Brazil
[30]. While our analyses, accounted for individual-level risk factors for pneumonia, it did not
account for temporal trends, including changes admission practices or pneumonia epidemiol-
ogy, which could account for an overall decline in pneumonia across this time period. This
may explain the unexpectedly large estimate that over 50% of all-cause pneumonia among
undervaccinated children is preventable at 90% PCV coverage among children under 5.
Our analyses did not identify a clear threshold at which PCV7-type IPD was eliminated—
with 5% of PCV7-type remaining at 90% coverage. Similarly, a prior study of the long-term
impacts of PCV against IPD in Australia reported reductions of 98% and 96% in VT IPD
among children <2 and 2 to 4 years old 8 years after vaccine introduction [3]. Our results may
reflect the inherent limitations of the vaccine or schedule or insufficient period of monitoring
post-PCV introduction to see full vaccine impacts; alternatively, there may be a lag in observ-
ing the full effects of indirect protection after reaching a certain PCV coverage [8], which was
not accounted for in this model.
While our analyses of PCV7-type IPD showed the steep declines in disease, especially up to
50% PCV coverage, we observed flatter associations between PCV coverage and both
PCV13-type IPD and all-cause pneumonia hospitalisations. These results are consistent with
previous studies indicating that higher coverage rates (58% to 75%) were required for substan-
tial indirect effects using PCV10 and PCV13. This may be explained by previous research indi-
cating lower vaccine effectiveness against the additional serotypes in PCV13 [35,36]. However,
there is a high degree of uncertainty around our PCV13 estimates since we have limited data
post-PCV13 introduction (1.5 years) and a small number of PCV13, non-PCV7 type IPD
cases. At the end of our study period, PCV13 coverage had only reached a median of 32.1%
among children under 5. Therefore, our analyses are unable to capture the full indirect effects
of PCV13, which are likely to increase as vaccine coverage rises over time. Smaller effect sizes
for the estimated indirect vaccine effects against all-cause pneumonia hospitalisations may be
due to the nonspecific nature of the outcome and/or differences in vaccine efficacy against the
different spectrum of serotypes causing pneumonia, compared to IPD [37].
The availability of a large population-based linked dataset and analyses at fine spatial and
temporal resolutions enabled precise evaluation of indirect effects in Australia; however, there
are some limitations. While our cohort is estimated to represent 97.5% of live births, it does
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not include children who have migrated into the 2 states or children who were never registered
at birth. SLA of residence was based on the mother’s SLA of residence at the time of the child’s
birth, and we do not have updated data on SLA of residence if a family or child moved. We
acknowledge that SLAs will not perfectly capture the boundaries of communities that interact
socially, in which to measure indirect protection. As with all observational studies, causation
cannot be assured. However, we observed a “dose effect” of PCV—for each decile increase in
coverage, there was a decline in pneumococcal disease, and, with the exception of parental
smoking, the prevalence of measured confounders changed very little over time. Our defini-
tion of undervaccinated included children who received 1 dose of vaccine under 12 months of
age who may benefit from some direct protection; however, majority of undervaccinated per-
son-time was in children who had no doses (83%), and sensitivity analyses among completely
unvaccinated children yielded similar results [38,39]. We consider the risk of misclassification
of vaccination status to be low, since vaccination status was determined using an immunisa-
tion registry, which has previously been demonstrated to underestimate coverage by less than
5% [40]. Lastly, an important limitation of this study is the potential for loss to follow-up in
children who have moved interstate (missing outcome data) or overseas (missing vaccination
and outcome data). From 2001 to 2012, the annual interstate out-migration of children less
than 5 years of age ranged from 1.6% to 2.2% in New South Wales and 1.4% to 2.1% in West-
ern Australia [41]. Data available from 2004 to 2012 indicate that overseas out-migration was
less common, ranging from 0.9% to 1.2% [42]. Since our analyses are for children up to 5 years
of age, we estimate that the cumulative unobserved loss to follow-up time to be less than 15%
—in line with recommendations for cohort [43]. Furthermore, we do not expect differential
loss to follow-up between vaccinated and undervaccinated children or as vaccine coverage
rises over time, since migration patterns have remained constant.
Our results support continuing efforts to increase vaccine coverage to maximise indirect
protection from PCV in Australia. In our study, PCV7-type IPD continue to decline as cover-
age increases among children under 5 years, suggesting that catch-up vaccination up to 5 years
of age may be important to maximise indirect effects—in line with previous research [44].
Indirect protection is important because it comprises a substantial component of overall
impact, improves cost-effectiveness of the vaccine, and protects infants too young to be vacci-
nated and adults. While our study does not include indirect effects on adult disease, prior
research suggests that in low-transmission settings, indirect effects in children are effectively
translated to indirect effects in adults, since children are the primary drivers of pneumococcal
transmission [45,46].
Understanding the coverage required to achieve indirect protection is of considerable
global interest in the potential for reduced dose (1 + 1) schedules [6] as the success of this pro-
gram relies on the continued generation of indirect protection for infants who have not
received sufficient doses to mount individual-level protection [6]. OurAU : PleaseconfirmthattheedittothesentenceOurfindingssuggestthatlowerratesofvaccinecoveragemay:::didnotaltertheintendedthoughtofthesentence:findings suggest that
lower rates of vaccine coverage may still be able to confer considerable indirect effects, and,
therefore, a 1 + 1 schedule may be suitable despite low PCV coverage. Additionally, we found
evidence that these trends are similar across a range of subgroups. However, our findings can-
not be directly extrapolated to other settings since degree of indirect protection is highly
dependent on local factors influencing pneumococcal transmission [28]. Other studies have
demonstrated lower than expected direct and indirect effects following PCV13 introduction in
Australia, which used a 3 + 0 schedule, compared to countries using a booster dose, such as the
UK (2 + 1 schedule) and the United States (3 + 1 schedule) [17,47]. As a result, Australia
implemented a switch from the 3 + 0 to 2 + 1 schedule in 2018. Further research beyond the
time frames available in this analysis is needed to document the longer-term impacts of
PCV13 introduction and the schedule change on indirect effects in Australia. Further research,
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using consistent and robust methodology, is also required to understand the relationship
between PCV coverage and indirect protection in a range of settings, particularly in high-
transmission settings. This will assist with understanding the role of PCV coverage as an alter-
native metric to determine if indirect effects are present in settings with insufficient disease
surveillance.
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